Positive News SentimentPositive NewsNASDAQ:PROK ProKidney (PROK) Stock Price, News & Analysis $0.72 +0.01 (+2.08%) Closing price 04:00 PM EasternExtended Trading$0.72 0.00 (-0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ProKidney Stock (NASDAQ:PROK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ProKidney alerts:Sign Up Key Stats Today's Range$0.70▼$0.7450-Day Range$0.51▼$1.0852-Week Range$0.46▼$4.35Volume496,772 shsAverage Volume676,226 shsMarket Capitalization$210.89 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingModerate Buy Company OverviewProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More… ProKidney Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScorePROK MarketRank™: ProKidney scored higher than 45% of companies evaluated by MarketBeat, and ranked 639th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingProKidney has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageProKidney has received no research coverage in the past 90 days.Read more about ProKidney's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ProKidney are expected to grow in the coming year, from ($0.57) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about ProKidney's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.48% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 19.3, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently increased by 1.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.48% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 19.3, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently increased by 1.92%, indicating that investor sentiment is decreasing. News and Social Media2.7 / 5News SentimentN/A News SentimentProKidney has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for ProKidney this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,175,419.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders41.49% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ProKidney's insider trading history. Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address PROK Stock News HeadlinesProKidney Reports First Quarter 2025 Financial Results and Business HighlightsMay 12, 2025 | globenewswire.comPROKIDNEY Earnings Preview: Recent $PROK Insider Trading, Hedge Fund Activity, and MoreMay 9, 2025 | nasdaq.comIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.May 29, 2025 | Colonial Metals (Ad)ProKidney Corp.March 30, 2025 | wsj.comHere's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn SituationMarch 27, 2025 | finance.yahoo.comProKidney reports FY24 EPS (62c), consensus (59c)March 17, 2025 | markets.businessinsider.comProKidney Reports Full Year 2024 Financial Results and Business HighlightsMarch 17, 2025 | globenewswire.comKuehn Law Encourages Investors of ProKidney Corp. to Contact Law FirmJanuary 31, 2025 | prnewswire.comSee More Headlines PROK Stock Analysis - Frequently Asked Questions How have PROK shares performed this year? ProKidney's stock was trading at $1.69 at the beginning of 2025. Since then, PROK stock has decreased by 57.0% and is now trading at $0.7270. View the best growth stocks for 2025 here. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) announced its earnings results on Monday, May, 12th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The business had revenue of $0.23 million for the quarter. Who are ProKidney's major shareholders? ProKidney's top institutional investors include Hennion & Walsh Asset Management Inc. (0.29%), Charles Schwab Investment Management Inc. (0.28%), Nuveen LLC (0.09%) and Bank of New York Mellon Corp (0.08%). Insiders that own company stock include Control Empresarial De Capital and Darin J Weber. View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProKidney own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProKidney investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Tesla (TSLA). Company Calendar Last Earnings5/12/2025Today5/29/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PROK CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+593.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.47 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-10.24% Debt Debt-to-Equity RatioN/A Current Ratio17.08 Quick Ratio17.09 Sales & Book Value Annual Sales$306,000.00 Price / Sales689.66 Cash FlowN/A Price / Cash FlowN/A Book Value($4.84) per share Price / Book-0.15Miscellaneous Outstanding Shares292,698,000Free Float170,651,000Market Cap$211.04 million OptionableOptionable Beta1.50 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:PROK) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.